Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Exclusion Criteria

• •Symptomatic splenomegaly;
• •Contraindications to interferon or ruxolitinib therapy;
• •Severe or significant comorbidities that may affect the participant's ability to participate in the study, as determined by the investigator;
• •History of major organ transplantation;
• •Pregnant or breastfeeding women;
• •History or current diagnosis of autoimmune thyroid disease (patients with controlled hypothyroidism on oral thyroid hormone replacement therapy may be included);
• •Documented evidence of any other autoimmune disease (such as active hepatitis, systemic lupus erythematosus, antiphospholipid antibody syndrome, or autoimmune arthritis);
• •Clinically significant bacterial, fungal, mycobacterial, parasitic, or viral infection such as active hepatitis or HIV infection (patients with acute bacterial infections requiring antibiotic treatment should be deferred from screening/enrollment until completion of antibiotic treatment);
• •Evidence of severe retinopathy or clinically significant ophthalmologic disease (due to diabetes or hypertension);
• •Current clinically significant depression or history of depression, or any suicidal attempt or tendency during screening;
• •Active bleeding or thrombotic complications;
• •History of any malignant tumor within the past 5 years (except for stage 0 chronic lymphocytic leukemia \[CLL\], cured basal cell carcinoma, squamous cell carcinoma, and superficial melanoma);
• •History of alcohol or substance abuse within the past year;
• •Presence of blasts in the peripheral blood within the past 3 months;
• •Use of any investigational drug or participation in any other clinical trial within 4 weeks prior to the first dose of the study drug, or failure to recover from any effects of previously administered study drugs;
• •The investigator deems the presence of any concurrent condition that may jeopardize the safety of the participant or the compliance to the protocol.